4.7 Article

DKC1 overexpression associated with prostate cancer progression

Journal

BRITISH JOURNAL OF CANCER
Volume 101, Issue 8, Pages 1410-1416

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605299

Keywords

prostate adenocarcinoma; dyskerin; siRNA; telomerase; apoptosis; tumour progression

Categories

Funding

  1. German Cancer Aid
  2. German Academic Exchange Service (DAAD)
  3. Jurgen-Manchot-Foundation

Ask authors/readers for more resources

BACKGROUND: Dyskerin encoded by the DKC1 gene is a predominantly nucleolar protein essential for the formation of pseudouridine in RNA and the telomerase RNA subunit hTR. Inherited mutations inactivating dyskerin cause dyskeratosis congenita, a syndrome with progeroid features characterised by skin defects and haematopoiesis failure, as well as cancer susceptibility. In this study, we report DKC1 overexpression in prostate cancers. METHODS: Expression of DKC1 was measured by quantitative RT-PCR in prostate cancer tissues in relation to hTR and the proliferation marker MKI167. Effects of dyskerin downregulation on proliferation, apoptosis and senescence of prostate cancer cell lines were determined. RESULTS: DKC1 was significantly overexpressed in prostate cancers, particularly in high-stage and recurring cases, correlating moderately with hTR and MKI167. Dyskerin downregulation in prostate carcinoma cell lines by siRNA diminished cell proliferation, but elicited neither apoptosis nor senescence. Apoptosis induction by TNF-alpha or tunicamycin was not enhanced. Long-term downregulation led predominantly to cell shrinking and loss of adhesion. INTERPRETATION: DKC1 upregulation in prostate cancers is common and likely to be necessary for extensive tumour growth. The phenotype of prostate carcinoma cell lines after dyskerin downregulation suggests that its most critical function is sustaining protein biosynthesis. Intriguingly, compromised function and overexpression of dyskerin can both contribute to cancer development. British Journal of Cancer (2009) 101, 1410-1416. doi:10.1038/sj.bjc.6605299 www.bjcancer.com Published online 15 September 2009 (C) 2009 Cancer Research UK

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available